Cargando…

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older

BACKGROUND: Although older patients are at increased risk for venous thromboembolism (VTE), thromboprophylaxis is underused because of bleeding concerns. The MARINER trial evaluated whether rivaroxaban reduced symptomatic postdischarge VTE in acutely ill medical patients. OBJECTIVES: We hypothesized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ageno, Walter, Lopes, Renato D., Goldin, Mark, Yusen, Roger D., Albers, Gregory W., Elliott, Gregory C., Halperin, Jonathan L., Hiatt, William R., Maynard, Gregory, Steg, Philippe Gabriel, Weitz, Jeffrey I., Suh, Eunyoung, Lu, Wentao, Barnathan, Elliot S., Raskob, Gary E., Spyropoulos, Alex C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	THROMBOSIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292378/ https://www.ncbi.nlm.nih.gov/pubmed/34314574 http://dx.doi.org/10.1111/jth.15477

Ejemplares similares

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
por: Raskob, Gary E., et al.
Publicado: (2021)

Hospital-based use of thromboprophylaxis in patients with COVID-19
por: Spyropoulos, Alex C, et al.
Publicado: (2020)

An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta‐analysis
por: Forgo, Gabor, et al.
Publicado: (2021)

Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2019)

Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta‐analysis
por: Horner, Daniel, et al.
Publicado: (2019)

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
por: Piazza, Gregory, et al.
Publicado: (2023)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Electronic alerts, comparative practitioner metrics, and education improve thromboprophylaxis and reduce venous thrombosis in community hospitals
por: Woller, Scott C., et al.
Publicado: (2018)

Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE
por: Cohen, Omri, et al.
Publicado: (2021)

COVID-19 Is Associated with Endothelial Dysfunction and Enhanced Plasma Thrombin Generation Despite Pharmacological Thromboprophylaxis
por: Kelliher, Sarah, et al.
Publicado: (2021)

Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population
por: Raskob, Gary E., et al.
Publicado: (2022)

Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer
por: Becattini, Cecilia, et al.
Publicado: (2022)

The impact of body weight on rivaroxaban pharmacokinetics
por: Barsam, Sarah J., et al.
Publicado: (2017)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients
por: Raskob, Gary E., et al.
Publicado: (2021)

The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study
por: Overvad, Thure F., et al.
Publicado: (2022)

Underuse of medical thromboprophylaxis in mobile elderly inpatients: The SWITCO65+ cohort
por: Blondon, Marc, et al.
Publicado: (2020)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
por: Cohen, Alexander Thomas, et al.
Publicado: (2011)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis
por: Zhang, Cong, et al.
Publicado: (2020)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
por: Soff, Gerald A., et al.
Publicado: (2019)

COVID-19 coagulopathy, thrombosis, and bleeding
por: Chan, Noel C., et al.
Publicado: (2020)

Targeted SERPIN (TaSER): A dual‐action antithrombotic agent that targets platelets for SERPIN delivery
por: Sanrattana, Wariya, et al.
Publicado: (2021)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

Clot‐targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis
por: Cabrera, David, et al.
Publicado: (2022)

Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
por: Scheres, Luuk J.J., et al.
Publicado: (2021)

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo
por: Perzborn, E, et al.
Publicado: (2014)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Global public awareness about atrial fibrillation
por: Wendelboe, Aaron M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pkscil0f4rt78i14t8svf2bgjo